Regeneron Pharmaceuticals (REGN) Cost of Revenue (2009 - 2026)

Regeneron Pharmaceuticals' Cost of Revenue history runs 18 years deep, the most recent figure standing at $360.7 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 30.88% year-over-year to $360.7 million; the TTM figure through Jun 2026 stood at $1.3 billion (up 18.01% YoY), while the FY2025 annual figure was $1.1 billion, up 4.92% from the prior year.
• Cost of Revenue for Q2 2026 stood at $360.7 million, down from $373.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $373.4 million in Q1 2026, with the low at $149.2 million in Q2 2022.
• The 5-year median for Cost of Revenue is $260.4 million (2023), against an average of $262.1 million.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue plunged 72.34% in 2022, then jumped 42.43% in 2023.
• Regeneron Pharmaceuticals' Cost of Revenue stood at $278.0 million in 2022, then decreased by 6.98% to $258.6 million in 2023, then grew by 26.37% to $326.8 million in 2024, then fell by 2.48% to $318.7 million in 2025, then advanced by 13.18% to $360.7 million in 2026.
• Business Quant data shows REGN's Cost of Revenue at $360.7 million in Q2 2026, $373.4 million in Q1 2026, and $318.7 million in Q4 2025.